NCT01225146View on ClinicalTrials.gov

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
IschemiaRetinal Vein OcclusionPathologic ProcessesRetinal DiseasesEye Diseases
Interventions
DRUG

ranibizumab

Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.

Trial Locations (1)

77030

Retina Consultants of Houston, Houston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

David M. Brown, M.D.

OTHER